

PTO/SB/21 (09-04)  
Approved for use through 07/31/2006. OMB 0651-0051  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/786,483	
	Filing Date	February 25, 2004	
	First Named Inventor	Jésus BENAVIDES et al.	
	Art Unit	1617	
	Examiner Name	CHONG, Yong Soo	
Total Number of Pages In This Submission	17 pgs.	Attorney Docket Number	ST01024 US CNT

**RECEIVED**  
**CENTRAL FAX CENTER**  
**JAN 20 2006**

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): <div style="border: 1px solid black; height: 40px; width: 100%;"></div>
<div style="border: 1px solid black; padding: 5px;"> <b>Remarks</b>          1. Amendment - 12 pgs.          2. Terminal Disclaimer - 2 pgs.          3. Terminal Disclaimer to Accompany Petition - 1 pg.          4. Claim Fee Sheet - 1 pg.       </div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Balaram GUPTA		
Date	January 20, 2006	Reg. No.	40,009

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300; Total No. of Pages Transmitted: 17 pgs.)	
Signature	
Typed or printed name	Brian Pritchett
Date	January 20, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Application of  
Jesus Benavides, et al.

Examiner: Chong, Yong Soo

**RECEIVED**  
**CENTRAL FAX CENTER**

Art Unit: 1617

Serial No.: 10/786,483

**JAN 20 2006**

Filed: February 25, 2004

Title: **Combination of a CB1 Receptor  
Antagonist and of a Product Which  
Activates Dopaminergic  
Neurotransmission in the Brain, the  
Pharmaceutical Compositions  
Comprising Them and their Use in the  
Treatment of Parkinson's Disease**

<b>Certificate of Mailing or Transmission</b>	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.	
Date of Deposit	January 20, 2006
Printed Name of Person Signing Certificate	Brian Pritchett
Signature	<i>Brian Pritchett</i>

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Transmitted herewith is an amendment in the above-identified application.

☐ No additional fee is required.

The fee has been calculated as shown below.

(1)	(2) CLAIMS REMAINING AFTER AMENDMENT*	(3)	(4) HIGHEST NUMBER PREVIOUSLY PAID FOR**	(5) PRESENT EXTRA	(6) RATE	(7) ADDITIONAL FEE
TOTAL CLAIMS	26	MINUS	24	2	50.00	100.00
INDEPENDENT CLAIMS	3	MINUS	3	0	200.00	0.00
MULTI-DEPENDENT CLAIMS(S), Per Application (360.00)						0.00
TOTAL AMENDMENT FEE FOR THIS AMENDMENT						\$100.00

\* If the entry in Column 2 is less than the entry in Column 4, write "0" in Column 5.

\*\* If the "Highest Number Previously Paid For" in Total Claims is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid For" in (Independent Claims) is less than 3, write "3" in this space.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. 1.16 which may be required by this paper or credit any overpayment to Account No. 18-1982. Two duplicate copies of this paper are enclosed.

Respectfully submitted,

January 20, 2006

*Balaram Gupta*Balaram Gupta, Reg. No. 40,009  
Attorney/Agent for Applicantsanofi-aventis Inc. LLC  
U.S. Patent Operations  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-3364  
Telefax (908) 231-2626

sanofi-aventis Docket No. ST01024 US CNT

**PATENT**

Docket No.: ST01024 US CNT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****RECEIVED  
CENTRAL FAX CENTER**In re Application of  
**Jesus Benavides**

Examiner: Chong, Yong Soo

**JAN 20 2006**

Art Unit: 1617

Serial No.: 10/786,483

Filed: February 25, 2004

**TELEFAX CERTIFICATE**Title: **Combination of a CB1 Receptor  
Antagonist and of a Product Which  
Activates Dopaminergic  
Neurotransmission in the Brain, the  
Pharmaceutical Compositions  
Comprising Them and their Use in the  
Treatment of Parkinson's Disease**I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, at (571) 273-8300 onJanuary 20, 2006

Date of Transmission

Brian R. Fitchett Brian R. Fitchett  
SignatureMail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450**AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 AND REPLY****PURSUANT TO 37 C.F.R. § 1.111**

Sir:

This is a Rule 111 Amendment in the above-identified patent application in response to the Office Action, paper no. 101705, dated, October 21, 2005, having a response due by January 23, 2006. It is respectfully requested that the following amendments and remarks be entered in this case.

Amendments to claims start on page 2.

Remarks to amendments and the outstanding office action begin on page 8.

01/24/2006 YPOLITE1 00000055 181982 10786483

01 FC:1202 100.00 DA

ST01024 US CNT

-1 of 12-